Last update 23 Jan 2025

Laitekang (Suzhou) Biopharmaceutical Co., Ltd.

Private Company|
2020|
Jiangsu Sheng, China

Overview

Tags

Neoplasms
Cytokines

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Top 5 Drug TypeCount
Cytokines1
Top 5 TargetCount
IL-2Rβγ(Interleukin-2 Rβγ)1

Related

1
Drugs associated with Laitekang (Suzhou) Biopharmaceutical Co., Ltd.
LAT-010
Target
IL-2Rβγ
Mechanism
IL-2Rβγ agonists
Active Org.
Laitekang (Suzhou) Biopharmaceutical Co., Ltd. [+1]
Originator Org.
Latticon Antibody Therapeutics, Inc
Active Indication
Solid tumor [+2]
Inactive Indication-
Drug Highest PhasePhase 1/2
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Laitekang (Suzhou) Biopharmaceutical Co., Ltd.
CTR20244740
/ Not yet recruitingPhase 1/2
评估LAT010在中国局部晚期或转移性实体瘤受试者中的安全性、耐受性、药代动力学/药效学、免疫原性和抗肿瘤活性的I/II期临床研究
[Translation] Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, immunogenicity and anti-tumor activity of LAT010 in Chinese subjects with locally advanced or metastatic solid tumors
100 Clinical Results associated with Laitekang (Suzhou) Biopharmaceutical Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Laitekang (Suzhou) Biopharmaceutical Co., Ltd.
Login to view more data
100 Deals associated with Laitekang (Suzhou) Biopharmaceutical Co., Ltd.
Login to view more data
100 Translational Medicine associated with Laitekang (Suzhou) Biopharmaceutical Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 2 Clinical
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
LAT-010
 ( IL-2Rβγ )		Solid tumor
More
Phase 2 Clinical
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free